In search of an evidence-based strategy for quality assessment of human tissue samples: report of the tissue Biospecimen Research Working Group of the Spanish Biobank Network

Margalida Esteva-Socias1,2, María-Jesús Artiga3, Olga Bahamonde4, Oihana Belar5, Raquel Bermudo6, Erika Castro5, Teresa Escámez7, Máximo Fraga8,9, Laura Jauregui-Mosquera10, Isabel Novoa11, Lorena Peiró-Chova4, Juan-David Rejón12, María Ruiz-Miró13, Paula Vieiro-Balo9, Virginia Villar-Campo10, Sandra Zazo14, Alberto Rábano15 and Cristina Villena1,2*

Abstract

The purpose of the present work is to underline the importance of obtaining a standardized procedure to ensure and evaluate both clinical and research usability of human tissue samples. The study, which was carried out by the Biospecimen Science Working Group of the Spanish Biobank Network, is based on a general overview of the current situation about quality assurance in human tissue biospecimens. It was conducted an exhaustive review of the analytical techniques used to evaluate the quality of human tissue samples over the past 30 years, as well as their reference values if they were published, and classified them according to the biomolecules evaluated: (i) DNA, (ii) RNA, and (iii) soluble or/and fixed proteins for immunohistochemistry. More than 130 publications released between 1989 and 2019 were analysed, most of them reporting results focused on the analysis of tumour and biopsy samples. A quality assessment proposal with an algorithm has been developed for both frozen tissue samples and formalin-fixed paraffin-embedded (FFPE) samples, according to the expected quality of sample based on the available pre-analytical information and the experience of the participants in the Working Group. The high heterogeneity of human tissue samples and the wide number of pre-analytic factors associated to quality of samples makes it very difficult to harmonize the quality criteria. However, the proposed method to assess human tissue sample integrity and antigenicity will not only help to evaluate whether stored human tissue samples fit for the purpose of biomarker development, but will also allow to perform further studies, such as assessing the impact of different pre-analytical factors on very well characterized samples or evaluating the readjustment of tissue sample collection, processing and storing procedures. By ensuring the quality of the samples used on research, the reproducibility of scientific results will be guaranteed.

Keywords: Quality, Pre-analytical variables, Biobank, Tissue, Biospecimen science

*Correspondence: cvillena@ciberes.org
1 Centro de Investigación Biomédica en Red Respiratory Diseases (CIBERES), Plataforma Biobanco Pulmonar CIBERES, Hospital Universitari Son Espases, Palma, Spain
Full list of author information is available at the end of the article

© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Human tissue samples obtained from biopsies, surgical specimens, organ transplants and autopsies are a great resource to find potential targets to aid clinical decisions such as diagnosis and treatment of diseases. Over the last decades, the use of human biospecimens has heavily increased in biomedical research in order to evaluate the outcome, survival, and new therapies for patients, and also to test new hypotheses related to the genetic and molecular basis of diseases. Besides, the constant technology advances for biomarker discovery have led to an increasing demand of large sets of human biospecimens and for new formats for the preservation of biospecimens suitable for these technologies, promoting also the creation of new human biorepositories [1].

Research on disease biomarkers is one of the main requirements for the progress of personalized medicine and its use for targeted therapies [2–5]. This clinical approach, particularly in Oncology, allows a great number of patients to access more efficient and safer therapeutic protocols, which have been selected according to molecular findings in tissue samples obtained from patients for diagnostic or therapeutic purposes. Indeed, many studies report the sustained discovery of different clinical biomarkers with potential application to personalized medicine [6]. However, most of them cannot be applied to clinical practice due to a lack of high sensitivity or/and specificity, compromising its reproducibility and its successful clinical implementation [7]. In this context, the recruitment of subjects, as well as the selection and management of tissues, is critical in biomarker research [8, 9].

Specifically, it is well known that the handling of human biospecimens during their collection, processing and storage can alter their characteristics and influence their quality, integrity and/or molecular composition [10]. These variations are considered as a bias in biomarker discovery, hindering the development of new targeted therapies.

As a result, there is a crucial need for the standardization of collection, processing and storage procedures to improve the quality of biospecimens, in order to enhance the reproducibility of biomarker development. Consequently, in recent years, a large number of strategies have been described to standardize and improve the quality control of human samples for their use in biomedical research, such as the “Standard PREanalytical Code” (SPREC) version 2.0, a method developed and agreed by the International Society for Biological and Environmental Repositories Biospecimen Science Working Group, which allows controlling the main pre-analytical factors that may have an impact on the integrity of the biological sample during its collection, processing and storage. SPREC assigns to each sample a code of 7 elements based on its pre-analytical characterization, helping to standardize the quality of the set of samples to be used [11].

There are also some guidelines to guarantee collection of clinical and pre-analytical data, such as BRISQ (Biospecimen Reporting for Improved Study Quality) [12]. The aim of BRISQ is to ensure the registration of human samples data, including the preanalytical factors which could influence the integrity, quality or molecular composition such as (a) type of pathology, (b) clinical status and features of the patient and (c) handling and preservation conditions (for example: stabilization, shipping and storage conditions).

However, despite the efforts made in the last years, the scientific community still lacks a standardized approach to ensure and evaluate the clinical and research usability of human tissue samples. For these reasons, we have undertaken to summarize and give a general overview of the current situation concerning quality assurance in human tissue biospecimens.

Literature review

The Spanish Biobank Network (SBN), formed by 39 biobanks, provides mainly samples to the scientific community to support biomedical research, as well as technical, ethical and legal advice, and other services related to human biological samples. One of its most developed areas is the Biospecimen Science, where mainly biologists and pathologists from 13 biobanks of the SBN, participate cooperatively in a working group focused on innovation in human tissues handling, (i) for improving standards on tissue collection, processing and storage, and (ii) for setting a global quality assessment method of human tissues for biomedical research.

Firstly, the SBN Biospecimen Science working group conducted an exhaustive literature review of the analytical techniques used to evaluate the quality of human tissue samples over the past 30 years, as well as their reference values if they were published, and classified them according to the biomolecules evaluated: (i) DNA, (ii) RNA, and (iii) soluble or/and fixed proteins for immunohistochemistry. The group focused on publications where colon, breast, kidney, lung, ovary or brain tissues were used, since these organs are the main source of samples collected by the participating biobanks.

Secondly, based on results of the literature review and the expertise of the participating biobanks, a proposal for quality assessment of tissues based on the type of preservation method and biomolecule of interest was led. The algorithm was purposed to classify the solid tissue samples according their expected quality, taking into account the type of analytical technique required for the research project.
For the design of the algorithm, the Group made a prioritization of pre-analytical factors defined by SPREC v.2.0 [11] and BRISQ [12] with the highest expected impact on the integrity of tissue samples according to the literature. So, the Working Group classified in three categories (optimal or non-effect, moderate or unknown effect and suboptimal quality) the expected quality of the nucleic acids integrity and fixed proteins for immunochemistry for each factor, both in snap-frozen and in formalin fixed-paraffin embedded (FFPE) tissue samples.

Identification of techniques for tissue quality assessment

More than 130 publications released between 1989 and 2019 were analysed, most of them reporting results based on the analysis of tumour and samples from biopsy procedures. Tables 1, 2, 3, 4 show a summary of the analytical techniques used to evaluate tissue quality, according to the analysed biomolecule (RNA, DNA, soluble proteins and antigenicity, respectively). They describe (i) the measurement method of the biomolecule, (ii) the analytical technique used, (iii) the parameters of the evaluated

| Table 1 Summary of publications evaluating quality of RNA samples |
|---------------------------------------------------------------|
| **Measurement method** | **Analytical technique** | **Evaluated parameter** | **Threshold** | **Organ** | **References** |
|-----------------------|--------------------------|------------------------|---------------|---------|---------------|
| Spectrophotometry | UV spectroscopy (A260/280) NanoDrop | Quantity and purity | Around 2 1.8 excellent 1.8–1.6 adequate 1.6 inadequate | Human trabecular bone Colon, articular cartilage and subchondral bone, brain | [13–18] |
| | UV spectroscopy (A260/230) NanoDrop | Quantity and purity | > 2 non contaminated RNA 2 contaminated RNA | Articular cartilage and subchondral bone | [16] |
| Electrophoresis | RIN, RIS, or equivalent | Integrity | ≥ 7 high-integrity RNA 6–7 adequate-integrity RNA 5–6 low integrity 3–5 partially degraded 1–3 totally degraded | Colon, kidney, placenta, articular cartilage and subchondral bone, trabecular bone, pancreas | [13, 14, 16, 19–27] |
| | DV200 | Integrity | > 70% high quality 50–70% medium quality 30–50% low quality < 30% too degraded | Brain and other tissue types | [37, 38] |
| | 28S:18S peak ratio | Integrity | Around 2 | Stomach, pancreas, liver, colorectal | [29] |
| | Electrophoretic profile | Integrity | 2 bands 2000 nt (18S), 4000 nt (28S) to (Non-degraded RNA) | Pancreatic tissue | [26, 27] |
| | RT-qPCR | 3′:5′ ratio | Integrity | 1–5 perfectly intact mRNA > 5 suggests degradation ≥ 10 denatured mRNA | N/A | [39] |
| | | Ct values | Functionality | Increasing Ct values of ABL1, FOSB and JUN genes suggest RNA degradation | Colon | [40] |
Table 2 Summary of publications evaluating quality of DNA samples

| Measurement method | Analytical technique                                     | Evaluated parameter     | Quality stratification threshold                                                                 | Organ                                          | References          |
|--------------------|-----------------------------------------------------------|-------------------------|--------------------------------------------------------------------------------------------------|------------------------------------------------|---------------------|
| Spectrophotometry  | UV spectroscopy (A260) NanoDrop                           | Quantity                | –                                                                                               | Pancreas, spleen, duodenum, liver               | [41]                |
|                    | Fluorochrome binding and fluorometer (Qubit)              | Quantity                | –                                                                                               | Pancreas, spleen, duodenum, liver, sarcoma,    | [41–45]            |
|                    | UV spectroscopy (A260/280) NanoDrop                       | Purity                  | 1.8–2.1 optimal; < 1.8 or > 2.1 contamination with RNA proteins or others                      | Lung adenocarcinoma, prostate                   | [44, 45]            |
|                    | UV spectroscopy (A260/230) NanoDrop                       | Purity                  | 2–2.2 optimal; lower ratios may indicate presence of contaminants                              | Prostate                                        | [44]                |
| Electrophoresis    | Pulsed field gel electrophoresis                          | Fragmentation           | Size distribution between 12 and 300 kb                                                        | –                                              | [46]                |
| Agarose gel, and capillary electrophoresis (DNA Integrity Number, DIN) | Fragmentation           |                        |                                                                                                 | Pancreas, spleen, duodenum, liver, sarcoma;    | [41, 47, 48]        |
| PCR                | Multiplex PCR and dHPLC/multiplex PCR and gel electrophoresis | Functionality           | Presence of the 300–to 400-bp amplicon indicates optimal quality, amplicon sizes ranging from 102 to 300 bp | Brain, colon and prostate                      | [44, 49]            |
|                    | Multiplex PCR and gel electrophoresis                     | Functionality           | Threshold not defined (amplicons between 268 and 1327 bp), optimal samples with amplification of 200 bp fragment or larger | Colon, uterine, myometrium and liver, breast   | [50, 51]            |
|                    | Multiplex PCR and microfluidic analysis                   | Functionality           | A QC ratio above 0.20 indicates optimal quality, ratios below 0.20 suggests moderate or poor quality | Lung                                           | [52]                |
| Multiplex digital PCR (dPCR) | Functionality                               |                         | Validation needed to establish stratification thresholds                                        | Lung                                           | [53]                |
| qPCR               | Functionality                                             |                         | Increasing qPCR ratio between frozen and FFPE tissue samples, 93 bp human GAPDH qPCR detection of 18S5 rRNA by qPCR (CT-value < 38), qPCR using FFPE QC kit and PreSeq QC assay, Q-ratio (with a value between 0 and 1), in which 41 bp and 129 bp targets were amplified by qPCR (KAPA human genomic DNA quantification and QC Kit-KAPA Biosystems). High Q-ratio: less fragmentation and vice versa | Liver, breast, tongue, prostate, sarcoma, lung adenocarcinoma, breast, gastric, colorectal | [43, 45, 47, 54, 55] |
| Multiplex qPCR     | Functionality                                             |                         | Percentage of functional templates (QFI, ranging from 0.03 to 24.9%), optimal > 3% to 6%         | Different sources                              | [56]                |

MF (somagen diagnostics) is a mixture of methanol and polyethylene glycol (90% and 10%, respectively)
Table 3  Summary of publications of quality control tools used in proteomics for evaluating the impact of pre-analytical factors

| Measurement method | Analytical technique | Evaluated parameter | Pre-analytical factor | Threshold | Organ | References |
|--------------------|----------------------|----------------------|-----------------------|-----------|-------|-----------|
| Spectrophotometry  | DC protein assay     | Concentration determined based on standard curve | N/A                   | N/A       | Colon, kidney | [57, 58]  |
|                    | BCA protein assay    |                      |                       |           |                   |           |
| Electrophoresis    | Western blot         | PCNA detection       | Fixation              | –         | Colon          | [57]      |
|                    |                      | Comparative evaluation of reactivity of fresh and FFPE using antibodies against GAPDH, tropomyosin, vinculin and myosin | –         | –         | Sheep tissue from skeletal muscle, liver, human hyperplastic thyroid tissue | [59]      |
| SDS-PAGE and silver staining | Size distribution | Sample age | High quality proteins are feasible to extract from 14 years samples | Liver | [60] |
| 2D-PAGE            | Comparison of 2D-PAGE gel protein profiles | Time to freeze | 30 min | Kidney | [61] |
| Mass spectrometry  | Immunoblotting       | P-p27 detection      | Fixation              | –         | Cell culture   | [62]      |
|                    | LC–MS/MS analysis    | Comparative analysis of peptide hits between fresh-frozen and FFPE samples | Fixation              | –         | Muscle         | [59]      |
|                    | Capillary isoelectric focusing coupled with RP LC–MS/MS | Protein overlap between fresh and FFPE tissue sections | Fixation              | –         | Kidney         | [58]      |
| Protein microarray | RPPAs                | Evaluation of increase and decrease percentage of phosphoproteins | Time to fixation | 20 min | Uterus, colon, lung, ovary, breast, lymph node | [64]      |
biomolecule, (iv) the threshold values and (v) the anatomical organ analysed.

It should be mentioned that the Group found little information focused on quality control of soluble proteins (Table 3) and antigenicity, including objective threshold values and analytical techniques used (Table 4). For this reason, the Working Group decided to include the most relevant publications regarding pre-analytical factors and its consequent effect on them. Consequently, Tables 3 and 4 include information regarding the pre-analytical factor under study for each cited reference and, if known, the threshold established to determine the effect of the pre-analytical factor on the sample.

### Consensus on an integrated algorithm for quality assessment

With the aim of systematizing the classification of human tissue samples according to their expected quality, a categorization proposal has been drawn up in the present study, based on SPREC and BRISQ tools as reference. Becker et al. [73] has already eloquently discussed in a review paper the importance of these pre-analytical factors for the meaningful translation of proteomic methods and findings to clinical practice. Next, in order to verify the functionality of the proposed categories and to establish reference ranges of analytical values, an algorithm was designed for decision-making based on the different...
biomolecules with different susceptibility profiles and on the type of sample preservation.

**A quality assessment proposal for frozen tissue samples**

Because of the increasing use of human frozen tissue specimens as a gold-standard for molecular analysis, a testing approach was designed for frozen tissue samples based on RNA evaluation (Fig. 1). As a first step, purity and concentration assessment of total RNA through spectrophotometry is recommended, since it is a quick and relatively simple method to evaluate (1) great deteriorations according to SPREC variables suffered during storage or analysis, or (2) a low cellular content related to its anatomical origin.

In case that an adequate concentration of total RNA is obtained and it is necessary to evaluate the suitability of the sample to perform gene expression studies, it would be advisable to evaluate the potential effect of pre-analytical factors (SPREC and BRISQ) on RNA integrity (Table 5) to decide if further optional analyses are required to determine whether a sample is suitable to the research purpose.

If predicted RNA quality is optimal according to pre-analytical factors, it is suggested to perform an integrity analysis of the total RNA through its visualization in an
Esteva-Socias et al. J Transl Med          (2019) 17:370

agarose gel and/or the calculation of the 28S:18S ratio using the RNA Integrity Number (RIN). According to recent publications, three ranges of RIN values have been set up as indicators of molecular integrity. A value greater than or equal to 7 is considered a non-degraded RNA, and therefore, it is assumed to be a high quality sample valid to carry out high-performance gene expression techniques (arrays, miRNA microarrays, RNA-Seq), and to be used in Next Generation Sequencing (NGS) of small RNA. In contrast, RIN values between 5 and 7 are indicative of RNA slight degradation and, finally, values below 4 indicate a high level of RNA degradation. The use of samples with RIN values included in the latter two groups is not valid for high-throughput technologies for gene expression analysis. However, they may be suitable for strategies whose main objective is to detect present or absence of a particular marker, such as Endpoint PCR or miRNA detection [19–21, 90, 91].

In contrast, if a moderate RNA quality level is estimated according to pre-analytical variables, more economic analytical techniques than RIN can be performed to evaluate sample quality. A good choice could be studying transcript degradation of a housekeeping genes set by RT-qPCR (GAPDH, ACTB, B2M, 18S, ATP5E, TUBB, for example) and evaluate the 3′/5′ ratio, as an indirect indicator of degradation and functionality [39, 92]. In most cases, RNA degradation is initiated by a gradual shortening of the poly(A) tail [93], which modifies the proportion of amplicons of the 3′ and 5′ region. This means that values close to 1.0 would indicate no degradation, while values further from 1.0 would indicate degradation and loss of functionality [94]. Samples with optimal quality to perform gene expression assays should present a rate of approximately 1.0 for most genes studied. Otherwise, if samples with a ratio significantly different from 1.0 are detected, they should not be considered for high performance analysis [92, 95].

Finally, if a sub-optimal quality is predicted (RIN values below 5), RIN determination itself is not a reliable measure of sample usefulness for RT-PCR or other applications, and accordingly other parameters should be taken into account in “fitness for purpose” decisions [96]. On those cases, it would be recommendable to perform endpoint PCR analyses, amplifying different fragments of several housekeeping genes, such as G6PD, TBP, HPRT, ACTB, GAPDH and then determine amplicon sizes by

| Table 5 Expected quality for frozen tissue samples based on RNA quality assessment according to pre-analytical factors prioritized following SPREC and BRISQ recommendations |
|---|
| **Type of codification** | **Variable** | **Optimal expected quality** | **Moderate expected quality** | **Sub-optimal expected quality** |
| BRISQ | Anatomical site | Colon, lung and liver | Fatty | – |
| BRISQ | Body temperature | 4 °C (post-mortem) [77] 37 °C (alive) | RT 18–28 °C (post-mortem) [77] | Unknown |
| SPREC | Type of sample | CEN, CLN, FNA, LCM, PLC, TIS | HAR, PEN, TCM | A12 |
| SPREC | Type of collection | A06, BCM, BPS, BSL, BTM, FNA, PUN, SFG, SSL, STM, TAC | A12 | A24, A48, A72 [77] |
| SPREC | Warm ischemia time | A, B, C, D, N | E | F, X |
| SPREC | Cold ischemia time | A, B, C, D [20, 78] | E, N | F, X [30, 66, 79] |
| SPREC | Fixation/stabilization type | OCT, PXT [80, 81] RNL [32, 82] SNP [24, 80, 81] ALL | None | Others (ACA, ALD, FOR, HST, NAA, NBF, XXX, ZZZ) [83] |
| SPREC | Fixation/stabilization time | D, E (PXT) [84] F (ALL, RNL) [85] N | A, B, C | X |
| SPREC | Long-term storage | A, J, N Q, S, W [86] | B, V, C, D, E, F, G, H, I, K, T, X | Z |
| BRISQ | Storage duration | < 5 years [88, 89] 5–20 years [89] > 20 years | – | – | – |
electrophoresis, loading the PCR product in an agarose gel, to start the quality control analysis. For samples showing differential size amplicons, it is assumed that whole RNA has enough quality for RT-qPCR assays. If only small amplicons are visible, it is considered that RNA has been degraded and it is only suitable for miRNAs analysis. If no amplicons are visible, the RNA quality is not enough for any gene expression study.

In summary, the expected quality of a sample and its pre-analytical variables should lead us to starting the process of quality assessment with a specific analytical technique or even a combination of them depending on the subsequent application (Fig. 1).

**A quality assessment proposal for formalin-fixed paraffin-embedded samples**

For the FFPE samples, according to the expected quality of the sample based on a first basic immunohistochemistry of CD31 and/or vimentin, a decision tree is proposed for the immunohistochemical process to be carried out (Fig. 2) in order to evaluate the antigenicity tissue quality. The antibodies selected for quality assessment were proposed based on the following criteria: (1) since they are widely used in Diagnostic Pathology routine, they could lead to an easier and rapid implementation of the quality control strategy and no changes would be necessary in work routines. Moreover, these antibodies are

---

**Fig. 2** Procedures proposed to evaluate antigenicity tissue quality, in order to classify the suitability of the sample for the expected application.
economically affordable and available from many reagent suppliers; (2) these antibodies are included in the Quality Assurance Program of the Spanish Society of Pathology (in Spanish: Sociedad Española de Anatomía Patológica, SEAP). This fact ensures that they are considered as antibodies used for current immunohistochemical diagnosis; (3) they hybridize with targets present in most human tissues, both healthy and pathological, which allows the quality control system to be robust.

Taking into account the above criteria, Ki-67 and TTF-1 were selected as nuclear markers, Vimentin and Cytokeratin AE1–AE3 as cytoplasmic markers; and CD31 and Beta-catenin as membrane markers. The selection of antibodies of different localizations inside cells also could help to understand how cellular location of a specific antigen can influence on its antigenicity preservation, which is currently a controversial concept.

So, in order to perform quality control on FFPE tissues a process based on two consecutives stages differentiated both by the implementation or not of an antigenic reconstitution procedure is recommended (Fig. 2). Antigenic retrieval allows recovering the antigenicity lost by the epitopes during the fixation process with formaldehyde preventing antibody recognition. The antigen retrieval process is considered as a key process for antigenicity preservation. It is advisable to use it in those samples where the concentration of the antigen to be identified is very low and in samples that have undergone prolonged periods of fixation.

We propose to carry out a first staining process with Vimentin and CD31 antibodies without antigenic reconstitution. Ki-67 is not included in this first step because it is well known that it has a low proportion of antigen and, therefore, for its proper function an antigen recovery process must be carried out. Those samples presenting high signal with Vimentin and CD31 stain, both in number of stained cells and in average intensity, would be considered as samples with optimal quality for carrying out immunohistochemistry (IHC) experiments. On the contrary, slides with low or no signal are recommended to be considered as samples of unknown quality.

Meanwhile, to evaluate the quality of those samples with unknown standards, it is proposed to carry out the second phase of the process but with a previous step of antigen retrieval. The procedure involves new staining processes, identical to the one carried out previously, but also including Ki-67 antibody. Those samples presenting a high and positive stain should be considered as samples with moderate quality to use IHC. The loss of signal between stage 1 (without antigen retrieval) and stage 2 (with antigen retrieval) would be related to pre-analytical factors affecting stability and sensitivity of epitope binding and recognition. Samples presenting no signal for the antibodies tested would have to be considered as samples of sub-optimal quality to perform IHC analysis.

Discussion and conclusions

Human biological samples from the most prevalent chronic and rare diseases are nowadays essential for advanced biomedical research. In the case of rare diseases, only collaborative approaches make it possible to collect a relevant number of samples with high quality associated clinical data [97, 98], while it is essential for any collection that the quality of samples remains homogenous. However, the emerging lack of reproducibility of scientific results is a relevant international problem, especially in the development of clinical biomarkers for the diagnosis, treatment and follow-up of a large number of diseases [99]. Regarding tissue samples, the availability of analytical techniques to assess their quality is important and necessary to ensure reproducibility of scientific results. Fortunately, the identification of pre-analytical factors affecting integrity of samples has been very well developed in international initiatives, as SPREC, BRISQ, MIABIS, etc. Nevertheless, a standardized and extensive method to determine the usability of a sample for a particular analytical technique, or even for general tissue samples quality evaluation, has not been developed in detail. The availability of these methods, as proposed in the present work, would reduce the bias posed by a specific group of samples selected for a study. In addition, these methods would allow the identification of threshold values to determine the impact of each pre-analytical factor on the quality, integrity and functionality of tissue samples, allowing the optimization of handling, preservation and storage procedures.

Recent developments in national and international regulations on human biospecimens for research present biobanks as organizations aimed at supplying biological material with the highest quality requirements to support biomedical research [100]. In Spain, biobanks have a specific national legal regulation and normally operate under quality management systems and standardized operation procedures (SOPs) to guarantee the minimum bias among preserved tissue samples. Biobanking staff is increasingly aware of the impact that pre-analytical factors may have on the handling of tissue samples and, moreover, of the importance of having analytical tools available for taking fundamental and strategic decisions in biobanks.

In 2009, with the aim of promoting the biomedical research in Spain, a solid network of biobanks, the SBN was created to improve the overall quality of samples for research use. At present, 39 biobanks are members of the network, including regional networks of biobanks, population biobanks, disease-specific biobanks and
neurological, complex and heterogeneous network, three common objectives have been established: (i) to promote the biomedical research by supplying samples with the maximum guarantee of quality; (ii) to collaborate in order to achieve the best service for the researchers; and (iii) to improve the knowledge in Biospecimen Science, in order to help on strategic decisions such as the implementation of a national quality program in biobanks. The entire network operates under a strategic plan 2018–2020, and the executive part is configured by 5 programs focused on (1) engagement of researchers and recruitment of collaborative scientific groups, (2) visibility and accessibility of the available collections and services, (3) R&D in biobanking, (4) internal and external communication, (5) specific training in biobanking procedures and network coordination. All the activity is supported by an internal structure formed by a Coordination Office, a Quality Committee, an Advisory Events Committee and an Advisory Ethical Committee, headed by a coordinator advised by the Steering Committee following the recommendations of an Advisory External Scientific Committee. Similar initiatives on quality issues are faced in Europe, solved in part with the establishment of the European Research Infrastructure for Biobanking and Biomolecular Resources (BBMRI-ERIC), formed by national biobank networks, dedicated to providing researchers with the support they need to find new treatments. In all these networks, a particular concern for global quality of samples and the implementation of specific quality tests are addressed in order to improve the homogenization and standardization, and in consequence, the reproducibility of the scientific results worldwide.

To help on that issue, our Working Group has conducted thorough review of the literature and has shared common expertise between its members on a wide range of preanalytical factors and analytical tests. As a result, we have designed, two algorithms for the classification of biobank tissue samples according to their expected level of performance in various analytical procedures. Both algorithms are based on (1) a selection of preanalytical data that are relevant for the final quality of samples; and (2) on a multi-step evaluation of samples by selected analytical methods that allow a final classification in terms of expected sample quality. One of the algorithms is aimed at defining sample quality for frozen tissue samples, while a second algorithm is directed to FFPE samples.

However, the great heterogeneity of human tissue samples and the large number of pre-analytical factors associated with the quality of samples makes it very difficult to harmonize the quality criteria. Nonetheless, assessing the integrity of the tissue itself and derived biomolecules, such as its antigenicity, as the method we propose, will help to evaluate if stored human tissue samples fit for the purpose for which they were collected, as well as if they are suitable for other unspecified uses not considered previously.

To conclude, the analytical strategies and techniques that are presented here constitute a first step to evaluate the real impact of pre-analytical factors. The implementation of such analytical methods will allow the periodic evaluation of the need to perform readjustments in collection, processing and storing processes to ensure the availability of well characterized human tissue samples for their use in biomedical research.

Abbreviations
AQUA: Automated Quantitative Analysis; BBMRI-ERIC: European Research Infrastructure for Biobanking and Biomolecular Resources; BRISQ: Biospecimen Reporting for Improved Study Quality; CIT: cold ischemia time; dHPLC: fluorescence detector-based denaturing high-performance liquid chromatography; FFPE: formalin-fixed paraffin-embedded; IHC: immunohistochemistry; LC: liquid chromatography; MS: mass spectrometry; N/A: non-available data; NGS: Next Generation Sequencing; R&D: research and development; RIN: RNA integrity number; RP: reverse phase; RPPAs: reverse phase protein array; RT-qPCR: reverse transcription quantitative polymerase chain reaction; SBN: Spanish Biobank Network; SDS-PAGE: sodium dodecyl sulphate polyacrylamide gel electrophoresis, SOPs: standardized operation procedures; SPREC: Standard PreAnalytical Code; TQI: tissue quality index.

Acknowledgements
We are grateful to the Spanish Biobank Network for supporting project.

Authors’ contributions
MES drafted the manuscript and all authors contributed drafting part of the manuscript, including tables and figures. AR and CV coordinated the draft and provided critical review of the manuscript. All authors also contributed with literature search. All authors read and approved the final manuscript.

Funding
This work was funded by the Ministerio de Ciencia, Innovación y Universidades of Spain and Instituto de Salud Carlos III (PI16/00528, PI16/00946, PI16/01207 and PI16/01276), co-funded by the Spanish Biobank Network (PT13/0010/0030, PT17/0015/0001, PT17/0015/0021, PT17/0015/0049, PT17/0015/0018, PT17/0015/0002, PT17/0015/0016, PT17/0015/0038, PT17/0015/0027, PT17/0015/0004, PT17/0015/0047, PT17/0015/0014, PT17/0015/0041, and PI17/0015/0006), European Regional Development Fund (FEDER) “A way to make Europe” and granted by Conselleria d’Innovació, Recerca i Turisme del Govern de les Illes Balears (TEC/002/2017).

Availability of data and materials
The data supporting the conclusions of this article are included within the article.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Centro de Investigación Biomédica en Red Respiratory Diseases (CIBERES), Plataforma Biobanco Pulmonar CIBERES, Hospital Universitari Son Espases, Palma, Spain. 2 Grupo de Inflamación, reparación y cáncer en enfermedades respiratorias, Institut d’Investigació Sanitària de les Illes Balears
1. Hughes SE, Barnes RO, Watson PH. Biospecimen use in cancer research over two decades. Biopreserv Biobank. 2010;8:889–97.
2. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24.
3. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84. https://doi.org/10.1056/NEJMoa052122.
4. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005;23:857–65.
5. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809–19.
6. Drucker E, Krapfenbauer K. Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine. EPMA J. 2013;4:37.
7. Taube SE, Clark GM, Dancey JE, McShane LM, Sigman CC, Gutman SL. A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. J Natl Cancer Inst. 2009;101:1453–63. https://doi.org/10.1093/jnci/djp334.
8. Pudlín L, Nuñorro F. Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic. Cell Oncol. 2015;38:39–48.
9. Ranshoff DF, Gourlay ML. Sources of bias in specimens for research about molecular markers for cancer. J Clin Oncol. 2010;28:698–704.
10. Ellervik C, Vaught J. Preanalytical variables affecting the integrity of human biospecimens in biobanking. Clin Chem. 2015;61:914–34.
11. Lehmann S, Guadagni F, Moore H, Ashton G, Barnes M, Benson E, et al. Standard preanalytical coding for biospecimens: review and implementation of the sample preanalytical code (SPREC). Biopreserv Biobank. 2012;10:366–74.
12. Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R, et al. Biospecimen reporting for improved study quality (BIRSEQ). Cancer Cytopathol. 2011;119:92–102. https://doi.org/10.1002/cncy.20147.
13. Cepollaro S, Della Bella E, de Biasi D, Visani M, Fini M. Evaluation of RNA from human trabecular bone and identification of stable reference genes. J Cell Physiol. 2018;233:4401–7. https://doi.org/10.1002/jcp.26519.
14. Hong SH, Baek HA, Jiang KY, Chung MJ, Moon WS, Kang MJ, et al. Effects of delay in the snap freezing of colorectal cancer tissues on the quality of DNA and RNA. J Korean Soc Coloproctol. 2010;26:316. https://doi.org/10.3393/jksc.2010.26.5.316.
15. Manchester KL. Use of UV methods for measurement of protein and nucleic acid concentrations. Biotechniques. 1996;20:968–70.
16. Le Bleu HK, Kamal FA, Kelly M, Retz JP, Zucskic MJ, Elbarbary RA. Extraction of high-quality RNA from human articular cartilage: Anal Biochem. 2017;518:134–8.
17. Haynes HR, Killick-Cole CL, Hares KM, Redondo J, Kemp KC, Moutasim KA, et al. Evaluation of the quality of RNA extracted from archival FFPE glioblastoma and epilepsy surgical samples for gene expression assays. J Clin Pathol. 2018;71:695–701.
18. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press; 1989. https://www.cabdirect.org/cabdirect/abstract/19901616061.
19. Botling J, Edlund K, Segersten U, Tahmasebsp;ooor S, Bengtsson M, Sundström M, et al. Impact of thawing on RNA integrity and gene expression analysis in fresh frozen tissue. Diagn Mol Pathol. 2009;18:44–52.
20. Freidin MB, Bhudia N, Lim E, Nicholson AG, Cookson WD, Moffatt MF. Impact of collection and storage of lung tumor tissue on whole genome expression profiling. J Mol Diagn. 2012;14:140–8. https://doi.org/10.1016/j.jmoldx.2011.11.002.
21. Liu NW, Sanford T, Srinivasan R, Liu JL, Khurana A, Aprilekova O, et al. Impact of ischemia and procurement conditions on gene expression in renal cell carcinoma. Clin Cancer Res. 2013;19:49–2.
22. Thompson KL, Pine PS, Rosenzweig BA, Turpaz Y, Retief J. Characterization of the effect of sample quality on high-density oligonucleotide microarray data using progressively degraded rat liver RNA. BMC Biotechnol. 2007;7:57. https://doi.org/10.1186/1472-6750-7-57.
23. Song SY, Jun J, Park M, Park SK, Choi W, Park K, et al. Biobanking of fresh-frozen cancer tissue: RNA is stable independent of tissue type with less than 1 hour of cold ischemia. Biopreserv Biobank. 2018;16:28–35.
24. Bao W-G, Zhang X, Zhang J-G, Zhou W-J, Bi T-N, Wang J-C, et al. Biobanking of fresh-frozen human colon tissue: impact of tissue ex-vivo ischemic times and storage periods on RNA quality. Ann Surg Oncol. 2013;20:1737–44.
25. Wolfe LM, Thiaagarajan RD, Boscolo F, Taché Y, Coleman RL, Kim J, et al. Banking placental tissue: an optimized collection procedure for genome-wide analysis of nucleic acids. Placenta. 2014;35:645–64.
26. Jun E, Oh J, Lee S, Jun H-R, Seo EH, Jang J-Y, et al. Method optimization for extracting high-quality RNA from the human pancreas tissue. Transl Oncol. 2018;11:800–7.
27. Kashofe K, Viertler C, Fichler M, Zatloukal K. Quality control of RNA preservation and extraction from paraform-embedded tissue: implications for RT-PCR and microarray analysis. PLoS ONE. 2013;8:e70714.
28. Betsou F, Bulla A, Cho SY, Clements J, Chuaqui R, Coppola D, et al. Assays for qualification and quality stratification of clinical biospecimens used in research: a technical report from the ISBER Biospecimen Science Working Group. Biopreserv Biobank. 2016;14:398–409.
29. Hu Y, Han H, Wang Y, Song L, Cheng X, Xing Y, et al. Influence of freeze-thaw cycles on RNA integrity of gastrointestinal cancer and matched adjacent tissues. Biopreserv Biobank. 2017;15:241–7.
30. Lalmohamed ZS, van den Braak RRJC, Oomen MHA, Arshad SP, Reginman PHJ, Uzermans JNM. Multicenter fresh frozen tissue sampling in colorectal cancer: does the quality meet the standards for state of the art biomarker research? Cell Tissue Bank. 2017;18(3):425–31.
31. White K, Yang P, Li L, Farshori A, Medina AE, Zielke HR. Effect of postmortem interval and years in storage on RNA quality of tissue at a repository of the NIH NeuroBioBank. Biopreserv Biobank. 2018;16:146–57.
32. Akta B, Sun H, Yao H, Shi W, Hubbard R, Zhang Y, et al. Global gene expression changes induced by prolonged cold ischemic stress and preservation method of breast cancer tissue. Mol Oncol. 2014;8:77–17.
33. Phillips T, Kusmartseva I, Gerling IC, Campbell-Thompson M, Wasserman C, Pugliese A, et al. Factors that influence the quality of RNA from the pancreas of organ donors. Pancreas. 2017;46:252–9.
34. Viana CR, Neto CS, Kerr LM, Palmero EI, Marques MMC, Colaiacovo T, et al. The interference of cold ischemia time in the quality of total RNA from frozen tumor samples. Cell Tissue Bank. 2013;14:167–73. https://doi.org/10.1007/s10561-012-9133-5.
35. Galissser T, Schneider C, Nasri S, Kanagaratnam L, Fichet C, Coquetel C, et al. Biobanking of fresh-frozen human adenocarcinomatous and normal colon tissues: which parameters influence RNA quality? PLoS ONE. 2016;11:1–17.
36. Reiman M, Laan M, Rull K, Söber S. Effects of RNA integrity on transcript quantification by total RNA sequencing of clinically collected human placental samples. *FASEB J*. 2017;31:3298–308.

37. Wimmer I, Tóthcsér AR, Brunner F, Rubino SJ, Ben CG, Weiner HL, et al. Systematic evaluation of RNA quality, microarray data reliability and pathway analysis in fresh, fresh frozen and formalin-fixed paraffin-embedded tissue samples. *Sci Rep*. 2018;8:1–17.

38. Illumina. Evaluating RNA Quality from FFPE. 2014. www.aii-us.com/product/fragment-analyzer.

39. Nolan T, Hands RE, Bustin SA. Quantification of mRNA using real-time RT-PCR. *Nat Protoc*. 2006;1:1559–82.

40. Musella V, Verderio P, Reid JF, Pizzamiglio S, Gariboldi M, Callari M, et al. Effects of warm ischemic time on gene expression profiling in colorectal cancer tissues and normal mucosa. *PLoS ONE*. 2013;8:e53406.

41. Simbolo M, Gottardi M, Corbo V, Fassan M, Mafficini A, Malpeli G, et al. DNA Qualification workflow for next generation sequencing of histopathological samples. *PLoS ONE*. 2013;8:e62692. doi.org/10.1371/journal.pone.0062692.

42. Kresse SH, Namlals HM, Lorenz S, Berner JM, Myklebost O, Bjerkæhagen B, et al. Evaluation of commercial DNA and RNA extraction methods for high-throughput sequencing of FFPE samples. *PLoS ONE*. 2018;13:1–12.

43. Nagahashi M, Shimada Y, Ichikawa H, Nakagawa S, Sato N, Kanieko K, et al. Formalin-fixed paraffin-embedded sample conditions for deep next generation sequencing. *J Surg Res*. 2017;202:125–32.

44. Patel PG, Selvarajan S, Güleraud K-P, Bartlett JMS, Lapointe J, Berman DM, et al. Reliability and performance of commercial DNA and RNA extraction kits for FFPE tissue cores. *PLoS ONE*. 2017;12:e0179732.

45. Watanabe M, Hashida S, Yamamoto H, Matsubara T, Ohtsuka T, Suzawa K, et al. Estimation of age-related DNA degradation from formalin-fixed and paraffin-embedded tissue according to the extraction methods. *Exp Ther Med*. 2017;14:2683–8.

46. Shao W, Kihn S, Kopp WC. Characterization of effect of repeated freeze and thaw cycles on stability of genomic DNA using pulsed field gel electrophoresis. *Biorxiv*. 2012;10:4–11.

47. Kresse SH, Namlals HM, Lorenz S, Berner JM, Myklebost O, Bjerkæhagen B, et al. Evaluation of commercial DNA and RNA extraction methods for high-throughput sequencing of FFPE samples. *PLoS ONE*. 2018;13:e0197456. doi.org/10.1371/journal.pone.0197456.

48. Gassmann M, Michoul B. DNA integrity number (DIN) with the agilent assay technical overview. https://www.agilent.com/cs/library/application/5991-5258EN.pdf.

49. Wang F, Wang J, Briggs C, Sicinska E, Gaston SM, Mamon H, et al. DNA degradation test predicts success in whole-genome amplification from diverse clinical samples. *J Mol Diagn*. 2007;9:441–51.

50. Turashvili G, Yang W, McKinney S, Kalloger S, Gale N, Ng Y, et al. Nucleic acid quantity and quality from paraffin blocks: defining optimal fixation, procurement and DNA/RNA extraction techniques. *Exp Mol Pathol*. 2012;92:33–43.

51. van Beers EH, Joosse SA, Ligtenberg MJ, Fles R, Hogervorst FBL, Verhoef K, et al. Estimation of age-related DNA degradation from formalin-fixed paraffin-embedded prostate biopsies. *BMC Med Res Methodol*. 2014;18:161.

52. Sah S, Chen L, Houghton J, Kempfmann J, Marko AC, Zeigler R, et al. Functional DNA quantification guides accurate next-generation sequencing mutation detection in formalin-fixed, paraffin-embedded tumor biopsies. *Genome Med*. 2013;5:77. doi.org/10.1186/gm481.

53. Ikeda K, Monden T, Kanoh T, Tsujie M, Izawa H, Haba A, et al. Extraction and analysis of diagnostically useful proteins from formalin-fixed, paraffin-embedded tissue sections. *J Histochem Cytochem*. 1998;46:397–403.

54. Shi SR, Liu C, Taylor CR. Standardization of immunohistochemistry for formalin-fixed, paraffin-embedded tissue sections based on the antigen-retrieval technique: from experiments to hypothesis. *J Histochem Cytochem*. 2007;55:1015–25.

55. Addics MF, Tanca A, Pagnozzi D, Crobu S, Fanciulli G, Cossoiu-Rocca P, et al. Generation of high-quality protein extracts from formalin-fixed, paraffin-embedded tissues. *Proteomics*. 2009;9:3815–23.

56. Kroll J, Becker KE, Kuphal S, Hein R, Hofstadter F, Bosserhoff AK. Isolation of high quality protein samples from punches of formalin fixed and paraffin embedded tissue blocks. *Histol Histopathol*. 2008;23:391–5.

57. Sarto C, Valsecchi C, Mocarelli P. Renal cell carcinoma handling and treatment. *Proteomics*. 2002;2:1627–9. doi.org/10.1002/1615-9861%2820020211%292%3A11%3C1627%3A3.0.CO;2-K.

58. Sunjit M, Lal SK. Glycogen synthase kinase-3 phosphates and regulates the stability of p27kip1 protein. *Cell Cycle*. 2007;6:580–8. https://doi.org/10.4161/cc.6.5.3899.

59. Balgley BM, Guo T, Zhao K, Fang X, Tavassoli FA, Lee CS. Evaluation of archival time on shotgun proteomics of formalin-fixed and paraffin-embedded tissues. *J Proteome Res*. 2009;8:917–25.

60. Espina V, Edmiston KH, Heiby M, Pierobon M, Scirio M, Merritt B, et al. A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. *Mol Cell Proteom*. 2008;7:1998–2018.

61. Combs SE, Han G, Mani N, Beruti S, Nerenberg M, Rimm DL. Loss of antigenicity with tissue age in breast cancer. *Lab Invest*. 2016;96:264–9.

62. Vassilakopoulou M, Parisi F, Siddiqui S, England AM, Zarella ER, Anagnostou V, et al. Preanalytical variables and phosphopeptide expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time. *Lab Invest*. 2014;95:334–41.

63. Neumeister VM, Parisi F, England AM, Siddiqui S, Anagnostou V, Zarella E, et al. A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue. *Lab Invest*. 2014;94:467–74.

64. Battifora H. Assessment of antigen damage in immunochemistry: the vimentin internal control. *Am J Clin Pathol*. 1991;96:669–71.

65. Hammond MEH, Hayes DF, Dowsett M, Allard DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. *J Clin Oncol*. 2010;28:2784–95.

66. Betsoa F, Barnes R, Burke T, Coppola D, DeSouza Y, Elason J, et al. Human biopsy specimen research: experimental protocol and quality control tools. *Cancer Epidemiol Prev Biomark*. 2009;18:1017–25.

67. Pierceall WE, Wolfe M, Suschak J, Chang H, Chen Y, Sprott KM, et al. Strategies for H-score normalization of preanalytical technical variables with potential utility to immunohistochemical-based biomarker quantitation in therapeutic response diagnostics. *Anal Cell Pathol*. 2011;34:159–68.

68. D’Andrea M, Howanski R, Saller C. MAP2 IHC detection: a marker of antigenicity in CNS tissues. *Biotech Histochem*. 2017;92:363–73.

69. Becker KE. Using tissue samples for proteomic studies—critical considerations. *Proteom Clin Appl*. 2015. doi.org/10.1002/prca.201401016.

70. Grizzle WE, Sexton KC, Bell WC. Quality assurance in tissue resources supporting biomedical research. *Cell Preserv Technol*. 2008;6:113–8.

71. Hammonds MEH, Hayes DF, Dowsett M, Allard DC, Hagerty KL, Badve S, et al. Human biopsy specimen research: experimental protocol and quality control tools. *Cancer Epidemiol Prev Biomark*. 2009;18:1017–25.
temperature: implications for study of proteins in human neurologic diseases and management of brain banks: a BrainNet Europe Study. J Neuropathol Exp Neurol. 2007;66:35–46.

78. Caboux E, Paciencia M, Durand G, Robinot N, Wozniak MB, Galateau-Salle F, et al. Impact of delay to cryopreservation on RNA integrity and genome-wide expression profiles in resected tumor samples. PLoS ONE. 2013;8:e79826.

79. Guerrera F, Tabbo F, Bessone L, Maletta F, Gaudiano M, Ercole E, et al. The influence of tissue ischemia time on RNA integrity and patient-derived xenografts (PDX) engraftment rate in a non-small cell lung cancer (NSCLC) Biobank. PLoS ONE. 2016;11:1–15.

80. Viertler C, Groelz D, Gündisch S, Kashofer K, Reischauer B, Riegman PHJ, et al. A new technology for stabilization of biomolecules in tissues for combined histological and molecular analyses. J Mol Diagn. 2012;14:458–66.

81. Groelz D, Sobin L, Branton P, Compton C, Wyrich R, Rainen L. Non-Salehi Z, Najafi M. RNA preservation and stabilization. Biochem Physiol. 2011;103:1871–83.

82. Howat WJ, Wilson BA. Tissue fixation and the effect of molecular fixatives on downstream staining procedures. Methods. 2014;70:12–9.

83. Florell SR, Coffin CM, Holden JA, Zimmermann JW, Gerwels JW, Summers BK, et al. Preservation of RNA for functional genomic studies: a multidisciplinary tumor bank protocol. Mod Pathol. 2001;14:116–28.

84. Andreasson A, Kiss NB, Juhlin CC, Ho A. Long-term storage of endocrine tissues at −80 °C does not adversely affect rna quality or overall histomorphology. Biopreserv Biobank. 2013;11:366–70.

85. Perkow SB, Barber JR, Zheng Q, Meeke AK, De Marzo AM, Platz EA, et al. Differential long-term stability of microRNA and RNU6B miRNA in 12–20 year old archived formalin-fixed paraffin-embedded specimens. BMC Cancer. 2017;17:32.

86. Shabihkhani M, Lucey GM, Wei B, et al. The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings. Clin Biochem. 2014;47:238–66.

87. Stewart GD, Baird J, Rae F, Harrison DJ. Utilizing mRNA extracted from small, archival formalin-fixed paraffin-embedded prostate samples for translational research: assessment of the effect of increasing sample age and storage temperature. Int Urol Nephrol. 2011;43:961–7.

88. Butler AE, Matveyenko AV, Kirakossian D, Park J, Gurlo T, Butler PC. Recovery of high-quality RNA from laser capture microdissected human and rodent pancreas. J Histotechnol. 2016;39:59–65.

89. Sun H, Sun R, Hao M, Wang Y, Zhang X, Liu Y, et al. Effect of duration of ex vivo ischemia time and storage period on RNA quality in biobanked human renal cell carcinoma tissue. Ann Surg Oncol. 2016;23:297–304.

90. Hatzis C, Sun H, Yao H, Hubbard RE, Merc-Bernstam F, Babiera GV, et al. Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers. J Natl Cancer Inst. 2011;103:1871–83.

91. Beelman CA, Parker R. Degradation of mRNA in eukaryotes. Cell. 1995;81:179–83.

92. Die JV, Obbero A, González-Verdejo C, Román B. Characterization of the 3′,5′ ratio for reliable determination of RNA quality. Anal Biochem. 2011;419:336–8.

93. Roberts L, Bowers J, Sensinger K, Lisowski A, Getts R, Anderson MG. Identification of methods for use of formalin-fixed, paraffin-embedded tissue samples in RNA expression profiling. Genomics. 2009;94:341–8.

94. Mathieson W, Marcon N, Antunes L, Ashford DA, Betsou F, Frasquilho SG, et al. A critical evaluation of the PAXgene tissue fixation system. Am J Clin Pathol. 2016;146:25–40.

95. Garcia M, Downs J, Russell A, Wang W. Impact of biobanks on research outcomes in rare diseases: a systematic review. Orphanet J Rare Dis. 2018;13:202. https://doi.org/10.1186/s13023-018-0942-z.

96. Monaco L, Crimi M, Wang CM. The challenge for a European network of biobanks for rare diseases taken up by RD-connect. Pathobiology. 2014;81:231–6.

97. Baker M. 1,500 scientists lift the lid on reproducibility. Nature. 2016;533:452–4.

98. Kinkorová J, Topolčan O. Biobanks in Horizon 2020: sustainability and attractive perspectives. EPMA J. 2018;9:345–53.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.